Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$1.25M$1.25M— vs Q3 2016 Net Income-$2.64M-$2.64MN/M vs Q3 2016 EPS Diluted-$0.34-$0.34N/M vs Q3 2016 Operating Income-$2,637,600N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-211.0%
Net margin-211.1%
ended Dec 31, 2016 · filed Feb 13, 2017 · 44 d after period end